Rebamipide Enema is Effective for Treatment of Experimental Dextran Sulfate Sodium Induced Colitis in Rats

Authors: Nakashima, Takako1; Maeda, Takashi1; Nagamoto, Hisashi1; Kumakura, Takeshi1; Takai, Masaaki2; Mori, Toyoki1

Source: Digestive Diseases and Sciences, Volume 50, Supplement 1, October 2005 , pp. S124-S131(1)

Publisher: Springer

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax      Refund Policy

OR

 
More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Abstract:

We investigated therapeutic efficacy of rebamipide using dextran sulfate sodium (DSS) induced colitis model in rats. Three percent DSS solution was given to rats for 9 days. After that, we evaluated the drug efficacy on colitis sustained with continuous drinking of 1% DSS. Twice-daily treatment with 0.3% or 1% rebamipide for 14 days significantly ameliorated the stool abnormality in the colitis model, preferentially suppressed hematochezia. The colonic mucosal lesion, determined by Alcian blue staining on day 24, was significantly reduced by rebamipide enema in a dose-dependent manner. Either rebamipide or 5-aminosalycilic acid (5-ASA) enema treated once daily significantly ameliorated colitis. The minimum effective dose of rebamipide was 0.3% in once-daily treatment, and that of 5-ASA was 10%. In a mechanistic study, the epithelial cell sheet formation of the T84 colon cancer cell was measured as an increase in generation of trans-epithelial electrical resistance in vitro. Rebamipide accelerated the increase, while 5-ASA conversely suppressed it. These results suggest that rebamipide enema is effective for treatment of experimental ulcerative colitis (UC).

Keywords: rebamipide; enema; dextran sulfate sodium; colitis; rat; T84

Document Type: Research article

DOI: 10.1007/s10620-005-2817-0

Affiliations: 1: Research Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192, Japan, 2: Research Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co. Ltd., 463-10 Kagasuno, Kawauchi-cho, Tokushima, 771-0192, Japan, Email: m_takai@research.otsuka.co.jp

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A